You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,436,700


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,436,700
Title: Anti-sense p21 k-ras
Abstract:Disclosed are methods and compositions for the selective inhibition gene expression through the application of antisense RNA technology. Antisense RNA constructs of the present invention employ the use of antisense intron DNA corresponding to distinct intron regions of the gene whose expression is targeted for down-regulation. In an exemplary embodiment, a human lung cancer cell line (NCI-H460a) with a homozygous spontaneous K-ras mutation was transfected with a recombinant plasmid that synthesizes a genomic segment of K-ras in antisense orientation. Translation of the mutated K-ras mRNA was specifically inhibited, whereas expression of H-ras and N-ras was unchanged. A three-fold growth inhibition occurred in H460a cells when expression of the mutated ras p21 protein was down-regulated by antisense RNA and cells remained viable. The growth of H460a tumors in nu/nu mice was substantially reduced by expressed K-ras antisense RNA.
Inventor(s): Roth; Jack A. (Houston, TX), Mukopadhyay; Tapas (Houston, TX), Tainsky; Michael (Houston, TX)
Assignee: Board of Regents, The University of Texas Systems (Austin, TX)
Application Number:07/987,235
Patent Claims:1. A nucleic acid molecule which selectively inhibits the expression of the p21 K-ras oncogene, the nucleic acid molecule encoding an antisense RNA molecule comprising sequences complementary to exons II and III and intron II of the p21 K-ras oncogene, the antisense coding region of the nucleic acid molecule being positioned under the control of the .beta.-actin promoter.

2. The nucleic acid molecule of claim 1, further defined as a DNA molecule.

3. The nucleic acid molecule of claim 1, further defined as a vector.

4. The nucleic acid molecule of claim 3, further defined as a plasmid.

5. The nucleic acid molecule of claim 3, further defined as a retrovirus.

6. An antisense RNA molecule which selectively inhibits the expression of the p21 K-ras oncogene, the antisense RNA molecule comprising sequences complementary to exons II and III and intron II of the p21 K-ras oncogene.

7. A DNA molecule capable of expressing an antisense RNA molecule in accordance with claim 6.

Details for Patent 6,436,700

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2019-08-20
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2019-08-20
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2019-08-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.